We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+38.18%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$186M
AUM Growth
+$4.75M
Cap. Flow
-$35.7M
Cap. Flow %
-19.19%
Top 10 Hldgs %
84.57%
Holding
20
New
2
Increased
2
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
OCRX
Ocera Therapeutics, Inc.
OCRX
+$6.57M
2
HRTX icon
Heron Therapeutics
HRTX
+$5.78M
3
TXMD icon
TherapeuticsMD
TXMD
+$3.71M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$2.29M

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$12.5M
2
DYAX
DYAX CORPORATION
DYAX
+$11.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.62M
4
TSRO
TESARO, Inc.
TSRO
+$4.58M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$4.38M

Sector Composition

Rank Sector Weight
1 Healthcare 65.48%
2 Miscellaneous 34.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$29.1M 15.63%
699,376
-138,424
-17% -$4.38M
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$25.9M 13.96%
1,545,999
-64,857
-4% -$897K
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$701M
$20.9M 11.25%
2,149,200
– –
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$19.5M 10.49%
2,586,980
-1,569,528
-38% -$11.9M
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.52B
$13.3M 7.18%
1,754,356
-426,300
-20% -$2.7M
KERX
6
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$13M 6.97%
1,000,273
-1,048,500
-51% -$12.5M
HRTX icon
7
Heron Therapeutics
HRTX
$63M
$9.86M 5.31%
1,095,735
+642,350
+142% +$5.78M
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
$9.14M 4.92%
+703,730
New +$6.57M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$329M
$8.92M 4.8%
719,075
+228,000
+46% +$2.29M
CHTP
10
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$7.54M 4.06%
1,701,170
-815,700
-32% -$2.76M
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.8B
$6.49M 3.49%
694,903
-576,400
-45% -$5.62M
TXMD icon
12
TherapeuticsMD
TXMD
$25.7M
$4.41M 2.37%
+16,930
New +$3.71M
TSRO
13
DELISTED
TESARO, Inc.
TSRO
$3.89M 2.09%
137,749
-123,381
-47% -$4.58M
ALBO
14
DELISTED
Albireo Pharma Inc
ALBO
$2.73M 1.47%
39,883
-2,837
-7% -$208K
HPTX
15
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$2.21M 1.19%
109,271
-108,300
-50% -$2.55M
ALXA
16
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$1.77M 0.95%
374,999
-25,000
-6% -$123K
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-357
Closed -$1.01M
MTEM
18
DELISTED
Molecular Templates, Inc.
MTEM
– –
-4,145
Closed -$3.18M
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-52,500
Closed -$1.56M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q4 2013 Portfolio in Review

As of Q4 2013, VHCP Management held 20 positions worth $186M, up 2.6% from $181M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

VHCP Management withdrew a net $35.7M in Q4 2013, closing 3 positions and reducing 11 holdings. Its most notable exit was Molecular Templates, Inc., an estimated $3.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in Ocera Therapeutics, Inc. worth $9.14M.

  • VHCP Management's largest Q4 2013 buy was Ocera Therapeutics, Inc.: 703,730 shares worth $9.14M.
  • VHCP Management added most to Heron Therapeutics in Q4 2013, an estimated $5.78M increase.
  • VHCP Management's biggest Q4 2013 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $12.5M.
  • VHCP Management fully exited Molecular Templates, Inc. in Q4 2013, selling an estimated $3.18M.
  • VHCP Management's ten largest holdings make up 85% of its $186M portfolio in Q4 2013.
  • VHCP Management opened 2 new positions and closed 3 in Q4 2013.
  • VHCP Management's portfolio value rose 2.6% quarter-over-quarter to $186M.

Based on VHCP Management's 13F filing for Q4 2013, filed 13 Feb 2014.